Survey: Independent docs concerned about ACA

Laura Pedulli | | Health Exec | Policy & Regulations

Many independent physicians are concerned that they are not benefitting from the Affordable Care Act (ACA), and many remain in the dark as to how to take advantage of it, according to a survey released by Acentec, a Calif.-based IT solutions and consulting service provider.

The survey, which targeted independent, ambulatory medical practices across the country, including specialists and primary care providers, found that:

  • 64 percent have not yet been given the opportunity to accept patients through their state’s or the federal government’s health insurance exchanges
  • 77 percent expect the ACA to have a negative impact on their practice
  • 48 percent don’t expect the ACA to impact their patient volume

“These results show that independent physicians still feel confusion on how to deal with the Affordable Care Act, and that many are apprehensive about the future of their practices as a result,” said Jeff Mongelli, CEO of Acentec, in a statement.

Read the entire survey here.

Laura Pedulli

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.